Abbott (NYSE:ABT) shares took a hit this week after Goldman Sachs reduced its rating on the stock to sell, from neutral. The dip also comes on the back of an urgent field safety notice warning on issues with the TactiCath quartz contact force ablation catheter. According to The Street, Goldman Sachs advised investors on June 1 […]
Chinese replacement heart valve maker Venus Medtech said today that it won a $37 million commitment from Goldman Sachs (NYSE:GS). Hangzhou-based Venus said it’s also won backing from Qiming Venture Partners, Sequoia Capital China, and Dinova Venture Capital. The company already has a transcatheter aortic valve replacement on the market in the People’s Republic and said a pulmonary […]
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
A group of private PE players including the Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and TPG acquired Biomet for $11.4 billion in 2007, placing medtech veteran Jeffrey Binder at the helm.
In a growing trend among device makers, Biomet Inc. announced that it’s exploring strategic options to spin out its 3i dental devices division.
The company is just testing the waters and a split isn’t guaranteed, but if completed the move will follow in some notable footsteps.
Interrad Medical Inc. raised $10 million in a Series C round it plans to spend on the development and commercialization of its SecurAcath catheter stabilization device.
The private placement with high-net-worth angels backing the Minneapolis-based med-tech company was brokered by the RBC Wealth Management Group.
"Recently raising 10 million dollars, in a volatile economy, is clearly a testament to the promise of the SecurAcath technology," said Joe Goldberger, Interrad president & CEO, in prepared remarks.
Analysts at a trio of investment advisory firms downgraded their estimates for C.R. Bard (NYSE:BCR) stock, which hasn’t fared well recently.